The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.

Disclosed are construction and application of a recombinant H5N8 subtype avian influenza virus carrying an mApple fluorescence reporter gene, and relates to the field of molecular biology and genetic engineering. The present disclosure provides a nucleic acid molecule which can be used for constructing the recombinant H5N8 subtype avian influenza virus. Compared with a wild H5N8 virus, the recombinant H5N8 subtype avian influenza virus has a weakened virulence, and can replicate in an SPF chicken lung and shows pathogenicity.

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.

The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.

Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.

The present invention relates to an mammalian non-pathogenic, highly-productive-in-embryonated-egg, heat-resistant, and attenuated clade 2.3.4.4c H5N6 recombinant influenza A virus, and a vaccine composition including the recombinant influenza virus and artificial H5 gene as active ingredients.

The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.

A recombinant virus containing a degron, a preparation method therefor, and an application thereof. At least one viral protein of the recombinant virus containing the degron contains at least one degron capable of being recognized by a protein degradation system of a host cell, wherein the degron comprises any one of or a combination of at least two of an amino acid sequence, a polypeptide, or a structural motif. Further provided are a nucleic acid molecule, a recombinant vector, a preparation method for the recombinant virus containing the degron, a preparation system for the recombinant virus containing the degron, a vaccine, an oncolytic virus, and a drug. The recombinant virus containing the degron can be recognized and degraded by the protein degradation system in the host cell, the replication capability is weakened or even removed, and after a corresponding vaccine, oncolytic virus or drug is prepared, a good effect and practical application value are achieved.

Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.